Liberty Capital Management Inc. decreased its stake in Danaher Co. (NYSE:DHR – Free Report) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,195 shares of the conglomerate’s stock after selling 387 shares during the quarter. Danaher makes up about 1.7% of Liberty Capital Management Inc.’s investment portfolio, making the stock its 16th largest position. Liberty Capital Management Inc.’s holdings in Danaher were worth $7,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently bought and sold shares of the company. AMF Tjanstepension AB bought a new stake in Danaher during the 3rd quarter worth approximately $5,923,000. CWM LLC grew its holdings in shares of Danaher by 0.5% during the third quarter. CWM LLC now owns 23,159 shares of the conglomerate’s stock worth $6,439,000 after purchasing an additional 125 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Danaher by 323.7% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,907 shares of the conglomerate’s stock valued at $1,643,000 after buying an additional 4,513 shares in the last quarter. Perfromance Wealth Partners LLC bought a new position in shares of Danaher in the third quarter valued at about $218,000. Finally, Ritholtz Wealth Management lifted its position in Danaher by 13.3% during the 3rd quarter. Ritholtz Wealth Management now owns 7,282 shares of the conglomerate’s stock worth $2,025,000 after buying an additional 857 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.
Insider Transactions at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is owned by insiders.
Analyst Ratings Changes
View Our Latest Stock Analysis on DHR
Danaher Trading Down 1.5 %
NYSE:DHR opened at $206.92 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business’s 50-day simple moving average is $232.72 and its 200-day simple moving average is $251.70. Danaher Co. has a fifty-two week low of $205.79 and a fifty-two week high of $281.70. The stock has a market capitalization of $149.45 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the firm earned $2.09 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.67 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is 20.45%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Retail Stocks Investing, Explained
- 3 Volatility ETFs to Help You Profit from Market Chaos
- Market Cap Calculator: How to Calculate Market Cap
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- What is the Hang Seng index?
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.